Treatment options for tauopathies. - Wikidata - awgldk - TriplyDB

Treatment options for tauopathies.

Treatment options for tauopathies.

http://www.wikidata.org/entity/Q53326015

about

Human fetal tau protein isoform: possibilities for Alzheimer's disease treatment Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options Frontotemporal Dementia.A powerful yeast model to investigate the synergistic interaction of α-synuclein and tau in neurodegeneration.Long-term treadmill exercise attenuates tau pathology in P301S tau transgenic mice.Will posttranslational modifications of brain proteins provide novel serological markers for dementias?Pharmacological Treatment of Mild Cognitive Impairment as a Prodromal Syndrome of Alzheimer´s Disease.Behavioral symptoms related to cognitive impairment.Autologous mesenchymal stem cell therapy for progressive supranuclear palsy: translation into a phase I controlled, randomized clinical study.Mitochondrial dysfunction in Parkinsonian mesenchymal stem cells impairs differentiation.Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.Neuroleptic malignant syndrome in an elderly patient with normal pressure hydrocephalus overlapping corticobasal degeneration.Progressive Motor Deficit is Mediated by the Denervation of Neuromuscular Junctions and Axonal Degeneration in Transgenic Mice Expressing Mutant (P301S) Tau Protein.

P2860

Q26829893-69430BFD-A247-445B-B0BD-AEDBBFB1471B Q28072101-B6A9BCE4-54C2-4ED1-9C7C-C71F3CD59AC1 Q30234793-A187A32E-876E-492B-A196-0FBB2102ABCF Q34581042-3768FA37-F26A-43D9-A5C6-AFDF5B67153D Q34794030-1C8565C6-7D48-4B83-88F0-BD51A3332956 Q36072517-4C7F34B5-AEF2-4F70-9037-B95E40E09577 Q36634130-D861C5A6-28E1-4509-92DC-D83E69A56FFB Q37211097-546652E2-37F5-4659-B200-A36AE3624172 Q37550552-8A36EE43-27A6-4DC6-8AD2-D2EDC39A74AF Q46142299-5E778E59-7FE0-4A14-BED9-101C0ED78FCF Q47113551-D40F9EE7-D37C-43E0-9C68-464B37DBE42C Q48498000-2847F03C-3F9A-4B4D-82C5-15A8D3533A64 Q51129031-E499CDD9-CF1C-4D5E-8A63-279AD1461247

P2860

Treatment options for tauopathies.

http://www.wikidata.org/entity/Q53326015

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Treatment options for tauopathies.

@en

Treatment options for tauopathies.

@nl

type

label

Treatment options for tauopathies.

@en

Treatment options for tauopathies.

@nl

prefLabel

Treatment options for tauopathies.

@en

Treatment options for tauopathies.

@nl

P1433

Q53326015-01BFB28F-5934-44F2-AA2C-38B2C8DF35C7

P1476

Q53326015-F088297C-D0CD-4B56-BF58-B160274E570D

P2093

Q53326015-2D9ABB73-66DB-478E-AE57-AB09E0A5ABE9

Q53326015-3735E240-FA94-4138-91A6-88AD30243D55

Q53326015-43302B24-86E0-44A8-B869-80A64E92AEF9

P2860

Q53326015-04AF11EB-6281-4359-8312-5707AE738C0F

Q53326015-0ECEF586-CD13-4C26-A209-B2DAB1BC9436

Q53326015-12AE599B-9400-4DC6-96B4-20A73FD4B6BE

Q53326015-14A05219-3C58-4CB6-99FF-E83F20246143

Q53326015-20A55970-2533-4017-A753-C58494DD7858

Q53326015-291E5A78-95DA-4B6C-9DD0-4DBE0CB52EC9

Q53326015-31044C05-C0CF-4264-A42A-6643A7499C2D

Q53326015-3107EFA5-6634-4A74-85B6-693FBB85443A

Q53326015-32B38E97-23FF-4698-BD47-91B8A1AD286F

Q53326015-35E84CF6-0D72-45D5-9449-31B9484B2A48

P2888

Q53326015-D13E6B81-8A18-431A-8BC1-7095886563D5

P304

Q53326015-59430EEE-44EF-4F7A-B8E5-CB5DD8F3EC2F

P31

Q53326015-568AAAC0-9745-4AE2-A0DA-71F6EECFBE84

P356

Q53326015-E38FAD43-314D-4391-9534-2A0A02EE04D2

P433

Q53326015-F37424E2-7D2F-4D0C-A999-CAB0C478F156

P478

Q53326015-C1E14A20-6ADD-48F2-8232-2A62B0FA690C

P50

Q53326015-73A21449-07E4-407E-9426-EDCE4F8A1306

P577

Q53326015-1736F67D-BA95-412B-9946-31519164A91D

P5875

Q53326015-A0A32F31-F1A5-419C-A575-76A9CDFB4D6D

P698

Q53326015-5F7FF9D3-3FF8-4B72-9F02-1B97CC7027DC

P356

S11940-012-0168-7

P1433

Current treatment options in neurology

P1476

Treatment options for tauopathies.

@en

P2093

David Prvulovic

http://www.w3.org/2001/XMLSchema#string

Fabian Fußer

http://www.w3.org/2001/XMLSchema#string

Tarik Karakaya

http://www.w3.org/2001/XMLSchema#string

P2860

Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options.

Biomarkers in frontotemporal lobar degenerations--progress and challenges.

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study.

Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis

Rivastigmine for dementia associated with Parkinson's disease.

Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.

Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management.

Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: Clinical observations as a basis for power calculations and safety analysis.

Progressive supranuclear palsy: new concepts.

Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia.

P2888

s11940-012-0168-7

P304

126-136

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11940-012-0168-7

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221807976

http://www.w3.org/2001/XMLSchema#string

P698

22307450

http://www.w3.org/2001/XMLSchema#string